Medicamen Biotech Limited

BSE:531146 Stock Report

Market Cap: ₹6.6b

Medicamen Biotech Past Earnings Performance

Past criteria checks 1/6

Medicamen Biotech's earnings have been declining at an average annual rate of -3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9% per year. Medicamen Biotech's return on equity is 3%, and it has net margins of 4.2%.

Key information

-3.0%

Earnings growth rate

-3.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.0%
Return on equity3.0%
Net Margin4.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Medicamen Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:531146 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,816763530
30 Jun 241,804813130
31 Mar 241,7931093350
31 Dec 231,7071272860
30 Sep 231,5971332620
30 Jun 231,4971542270
31 Mar 231,4091482180
31 Dec 221,2501371980
30 Sep 221,2201371780
30 Jun 221,2101431590
31 Mar 221,1541491560
31 Dec 211,1391581360
30 Sep 211,1421501230
30 Jun 211,125140970
31 Mar 211,127121960
31 Dec 201,150110970
30 Sep 201,1741161000
30 Jun 201,222123970
31 Mar 201,2551331010
31 Dec 191,353136900
30 Sep 191,241124850
30 Jun 191,210123790
31 Mar 191,227120860
31 Dec 181,187110940
30 Sep 181,229117970
30 Jun 181,183108910
31 Mar 181,115101990
31 Dec 171,045941000
30 Sep 1796281950
30 Jun 1791265750
31 Mar 1782552710
31 Dec 1678258550
30 Sep 1672326520
30 Jun 1667318540
31 Mar 166735610
31 Dec 15679-131370
30 Sep 15667-21370
30 Jun 15760-1650
31 Mar 157794680
31 Dec 1481601290
30 Sep 14807-11260
30 Jun 14738-1570
31 Mar 1473211230
31 Dec 13696-71250

Quality Earnings: 531146 has high quality earnings.

Growing Profit Margin: 531146's current net profit margins (4.2%) are lower than last year (8.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 531146's earnings have declined by 3% per year over the past 5 years.

Accelerating Growth: 531146's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 531146 had negative earnings growth (-43.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).

Return on Equity

High ROE: 531146's Return on Equity (3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:20
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medicamen Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research